盐酸文拉法辛合并舒肝解郁胶囊与多虑平治疗躯体形式障碍的对照研究  

Comparative Study on Venlafaxine Combined Shuganjieyu Capsule with Doxepin in the Treatment of Somatoform Disorders

作　　者：赵云[1] 单敬[1] 贾会珍[1] 柴瑞莉[1] 田晓锦[1] 

机构地区：[1]中国．河北省衡水市哈励逊国际和平医院心理门诊,053000

出　　处：《中国健康心理学杂志》2011年第11期1312-1314,共3页China Journal of Health Psychology

基　　金：2007年衡水市科学技术研究与发展指导计划项目(编号:07027z)

摘　　要：目的探讨盐酸文拉法辛合并舒肝解郁胶囊对躯体形式障碍的疗效、不良反应和依从性。方法采用随机分组的方法,将156例躯体形式障碍患者分为治疗组77例,对照组79例,治疗8周,用症状自评量表(SCL-90)和副反应量表(TESS)评定疗效和不良反应。结果治疗组与对照组比较躯体形式障碍的起效时间有统计学意义(t=2.71,P<0.05),不良反应方面有显著性差异(χ2=49.01,P<0.01),依从性有显著差异(χ2=6.62,P<0.01)。结论盐酸文拉法辛合并舒肝解郁胶囊与多虑平比较对躯体形式障碍起效快,不良反应小、依从性好,值得临床应用和推广。Objective To study the clinical effects,side effects and compliance of venlafaxine combined Shuganjieyu capsule in treatment of somatoform disorders.Methods A total of 156 patients who met CCMD-3 for somatoform disorders were randomly divided into venlafaxine（77 patients） and doxepin（79patients） group,and treated for 8 weeks.The clinical effects and side effects were tested with SCL-90 and TESS.Results The clinical effect of venlafaxine was significant difference to doxepin（t=2.71,P0.05）.The venlafaxine had less side effects than doxepin（χ2=49.01,P0.01）,The venlafaxine had significant differences compared with doxepin in compliance with medication（χ2=6.62,P0.01）.Conclusion Venlafaxine combined shuganjieyu capsule is an effective method with fewer side effects in the treatment of somatoform disorders.

关 键 词：盐酸文拉法辛 舒肝解郁胶囊 多虑平 躯体形式障碍 

分 类 号：R749[医药卫生—神经病学与精神病学]